Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Fusion Proteins
Studies from Imperial College London, Imperial College yield new information about fusion proteins
May 21st, 2008
New research, 'CD200-FC, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis,' is the subject of a report. According to a study from London, the United Kingdom, "The CD200 receptor (CD200R) is an inhibitory receptor expressed by myeloid cells that is postulated to play an important role in regulation of the immune system. The purpose of this study was to evaluate the efficacy of a soluble ligand of CD200R in established collagen-induced arthritis (CIA) in mice and to analyze changes in cytokine expression following therapy in order to understand its primary mechanism of action." ...
Source: Immunotherapy Weekly (2008-05-21)
|
